Successfully results from clinical study with Vacc-4x and Endocine
Oslo 10.05.2012 – Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x together with Endocine This New Option May Offer Easier Treatment Access for HIV…
HIV treatment with nasal-drop form
Oslo 10.04.2012 – Bionor Pharma ASA (OSE: BIONOR) today announces that the placebo controlled study of nasally administered HIV therapeutic vaccine Vacc-4x in combination with Eurocine Vaccines` Endocine has been…
Vacc-4x phase IIB
Oslo 15.02.2012 – With final review of phase IIb viral load data completed, researchers confirm statistically significant reduction of HIV viral load on Vacc-4x compared to placebo. Bionor Pharma announced…
Vacc-4x presented at AIDS Vaccine 2011 in Bangkok
(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on “Global HIV Vaccine Enterprise” press conference at AIDS Vaccine 2011 in Bangkok. Results from Phase IIB Placebo Controlled Study of Bionor’s…
Clinical status for Vacc-4x and Revlimid®
BioCentury Publications, Inc., a leading provider of value-added information on strategic issues in life science, has in their report BioCentury Week in Review Aug 29, 2011, published the clinical status of…
New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)
Oslo – 25.08.11 – Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug The study will determine: The target patient…
BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV
New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of…
Successful therapeutic vaccination with Vacc-4x
Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection Bionor Pharma announced today presentation of data from its international multicenter double-blinded placebo-controlled phase…
Vacc-4x shows statistically significant reduction viral load
Further analysis of Vacc-4x phase IIb study shows a statistically significant reduction in viral load over placebo – Bionor Pharma reverses decision to put Vacc-4x on hold.